BIT Capital GmbH Takes Position in GH Research PLC $GHRS

BIT Capital GmbH acquired a new stake in GH Research PLC (NASDAQ:GHRS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $635,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Goldman Sachs Group Inc. increased its stake in shares of GH Research by 631.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 80,986 shares of the company’s stock valued at $1,029,000 after purchasing an additional 69,911 shares in the last quarter. AdvisorShares Investments LLC increased its stake in shares of GH Research by 24.3% in the 4th quarter. AdvisorShares Investments LLC now owns 67,112 shares of the company’s stock valued at $852,000 after purchasing an additional 13,121 shares in the last quarter. Jefferies Financial Group Inc. increased its stake in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of GH Research in the 4th quarter valued at about $128,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of GH Research in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Stock Down 7.8%

NASDAQ:GHRS opened at $21.43 on Friday. The stock’s fifty day moving average is $19.54 and its two-hundred day moving average is $16.48. GH Research PLC has a 52 week low of $11.32 and a 52 week high of $25.94. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -23.29 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, sell-side analysts expect that GH Research PLC will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GHRS shares. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. Cantor Fitzgerald lifted their price target on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Needham & Company LLC lifted their price target on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Finally, Guggenheim set a $34.00 price objective on GH Research and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GH Research has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.